

# 293T human OX40 Cell Line

Cat. No: KC-0282

Version 17103102

I. Cell Line Information.....	1
II. Background.....	1
III. Cell Line Generation.....	2
IV. Characterization using FACS.....	2
V. Application.....	2
VI. Cell Resuscitation.....	2
VII. Cell Freezing.....	3
VIII. References.....	3

## I. Cell Line Information

<b>Catalog number</b>	KC-0282
<b>Cell line name:</b>	293T human OX40 Cell Line
<b>Gene ID/Accession #:</b>	NM_003327.3
<b>Host cell line</b>	293T
<b>Cell type:</b>	Human embryonic kidney
<b>Description:</b>	HEK293T cell line stable expressing exogenous human OX40 gene
<b>Quantity:</b>	One vial of frozen cells (5X10 <sup>6</sup> per vial)
<b>Stability:</b>	Stable in culture over a minimum of 10 passages
<b>Application:</b>	Drug screening and biological assays
<b>Freeze medium:</b>	70% DMEM + 20% FBS + 10% DMSO
<b>Propagation medium:</b>	DMEM + 10% FBS + 0.5ug/ml Puromycin
<b>Selection marker:</b>	Puromycin
<b>Morphology:</b>	Fibroblastoid cells growing as monolayer
<b>Subculture:</b>	Split saturated culture 1:4~1:5 every 2~3 days; seed out at about 1-3 x 10 <sup>5</sup> cells/ml
<b>Incubation:</b>	37 °C with 5% CO <sub>2</sub>
<b>Doubling time:</b>	Approximately 30 hours
<b>Mycoplasma status:</b>	Negative
<b>Biosafety level:</b>	1
<b>Storage:</b>	Liquid nitrogen immediately upon receiving

## II. Background

OX40, also named as CD134 or tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), is a member of the TNFR superfamily acting as co-stimulatory immune checkpoint molecule expressed on the activated T cells. OX40 plays a critical role in maintaining of immune response and lead to a memory immune response. OX40-OX40 Ligand interaction is involved in allergic airway inflammation, graft-versus-host disease and autoimmune disease

and cardiovascular disease.

### III. Cell Line Generation

293T human OX40 cell line was generated using lentiviral vector expressing human OX40 sequence.

### IV. Characterization using FACS




Figure: Characterization of OX40 overexpressing in 293T stable clones using OX40.

### V. Application

Hybridoma or Binders of ligand screening with FACS.

### VI. Cell Resuscitation

1. Prewarm culture medium (DMEM supplemented with 10% FBS and 0.5ug/ml puromycin) in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0 mL complete culture medium.
5. Spin at ~ 125 x g for 5~7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO<sub>2</sub> incubator.
8. Split saturated culture 1:4 ~ 1:5 every 2~3 days; seed out at about 1-3 x 10<sup>5</sup> cells/ml.

## VII. Cell Freezing

1. Prepare the freezing medium (70% DMEM + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least  $3 \times 10^6$  cells/ml in chilled freezing medium.
6. Aliquot 1 ml of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a  $-80^{\circ}\text{C}$  freezer.
8. Transfer vials to liquid nitrogen for long-term storage.

## VIII. References

1. Ishii, Naoto, Takeshi Takahashi, Pejman Soroosh, and Kazuo Sugamura. 2010. "OX40-OX40 Ligand Interaction in T-Cell-Mediated Immunity and Immunopathology." In, 105:63–98. *Advances in Immunology*. Elsevier. doi:10.1016/S0065-2776(10)05003-0.
2. Aspeslagh, Sandrine, Sophie Postel-Vinay, Sylvie Rusakiewicz, Jean-Charles Soria, Laurence Zitvogel, and Aurélien Marabelle. 2016. "Rationale for Anti-OX40 Cancer Immunotherapy." *European Journal of Cancer* 52 (January). Elsevier: 50–66. doi:10.1016/j.ejca.2015.08.021.

**Kyinno Biotechnology Co., Ltd.**

Yizhuang Biomedical Park, No. 88, Beijing, China

Tel: +86-10-58222702

E-mail: [bd@kyinno.com](mailto:bd@kyinno.com)

Web: [www.kyinno.com](http://www.kyinno.com)

**For Research Use Only**